Home Cart Sign in  
Chemical Structure| 917910-45-3 Chemical Structure| 917910-45-3

Structure of MK-6892
CAS No.: 917910-45-3

Chemical Structure| 917910-45-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MK-6892 is a highly potential GPR109A agonist with Ki value of 4.0 nM.

Synonyms: MK-6892

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MK-6892

CAS No. :917910-45-3
Formula : C19H22N4O5
M.W : 386.40
SMILES Code : O=C(O)C1=C(CCCC1)NC(C(C)(CC2=NC(C3=NC=C(C=C3)O)=NO2)C)=O
Synonyms :
MK-6892
MDL No. :MFCD20528236

Safety of MK-6892

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of MK-6892

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CHO-K1 cells 100 μM 30 cycles Evaluate the inhibitory effect of DLT on 5HT2AR PMC10665550
HEK293 cells 10 µM 2 hours Evaluate the effect of SR9009 on a luciferase reporter driven by the Bmal1 promoter PMC10518311

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/C mice Orthotopic colon cancer model Oral 45 mg/kg Administered on days 4, 6, 8, 10, and 12, lasting until day 12 MK-6892, as an agonist of the GPR109A receptor, significantly enhanced the antitumor effect when combined with microgels, achieving a tumor inhibition rate of 93%. PMC11089779
Balb/C mice Orthotopic colon cancer model Oral administration 45 mg/kg Administered on days 4, 6, 8, 10, and 12, continued until day 21 Evaluated the antitumor effect of MK-6892 combined with probiotic microgels, showing significant tumor growth inhibition with a tumor inhibition rate of 93%. PMC11089779

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.94mL

2.59mL

1.29mL

25.88mL

5.18mL

2.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories